content_image/158943.jpg
## 戦戦 Chapter 3 Business Strategy 

## Business Strategy 

## For Sustainable Growth 

This section looks at the business environment faced by Astellas, as well as the business model and strategic priorities that we are targeting to realize sustainable growth over the medium to long term. 

## Business Model & Mid-Term Management Plan 

## Business Model 

Astellas pursues a Global Category Leader (GCL) business model, focusing resources on the creation of innovative pharmaceuticals based on its excellent R&D capabilities. Under the GCL business model, our aim is to establish a competitive edge as a leader in multiple highly specialized therapeutic areas with a high level of unmet medical need, and to supply high-value-added pharmaceuticals worldwide. In this way, we are targeting the sustainable enhancement of enterprise value by contributing to better health for people around the world. 

## Three Growth Strategies under the 2014 Mid-Term Management plan 

We have established GCL status for Astellas in the areas of urology and transplantation, two categories where we are globally competitive. We are currently build- ing up our business platform to develop oncology as a third GCL area. 

## 2014 Mid-Term Management Plan 

Under the 2014 Mid-Term Management Plan covering the five-year period from fiscal 2010 to fiscal 2014, we are pursuing three types of growth strategies; a therapeutic area strategy, a regional strategy and an R&D innovation strategy—underpinned by a focus on efficient operations. 

<img src='content_image/158943.jpg'>

